Navigation Links
IDRI Develops Novel Tuberculosis Vaccine, New Study in Science Reports
Date:10/15/2010

SEATTLE, Oct. 16 /PRNewswire-USNewswire/ -- The Infectious Disease Research Institute (IDRI) announces it has developed a new tuberculosis (TB) vaccine that protects against TB including drug-resistant strains of the disease in animal studies. The results of these studies are published in Science Translational Medicine today.

Drug-resistant tuberculosis is a major global public health concern. According to the World Health Organization, approximately 9 million people are infected with TB, and close to half a million are resistant to multiple drugs that once effectively treated the disease. Two million people die of TB each year.

Though a childhood vaccine for tuberculosis, BCG, has been widely used for decades, its protection wanes over time, and new virulent forms of the disease are spreading. Control activities are limited without new vaccines, immunotherapeutics, and drugs to protect against these killer strains of TB.

IDRI's TB vaccine enhances and extends BCG and protects against drug-resistant strains through its unique combination of a molecule containing four tuberculosis proteins with a synthetic adjuvant, also developed at IDRI.

Dr. Rhea Coler, Vice President of Preclinical Biology and one of the study's Principal Investigators, explains, "Combining proteins in a vaccine is important because tuberculosis bacilli are variable, and no single protein will be effective against all strains."  In addition, because of human genetic diversity, individuals will respond differently to different proteins. A combination of proteins, such as exist in natural tuberculosis bacteria, increases the vaccine's efficacy.

The vaccine is now being developed for clinical testing in humans.

About IDRI – Translating science into global health solutions

IDRI is a Seattle-based not-for-profit organization committed to applying innovative science to the research and development of products to prevent, detect, and treat infectious diseases of poverty. By integrating capabilities—including preclinical vaccinology, manufacturing, and clinical trials—IDRI strives to create an efficient pathway bringing scientific innovation from the lab to the people who need it most.

For more information, go to www.idri.org  


'/>"/>
SOURCE Infectious Disease Research Institute (IDRI)
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. Diplomat Specialty Pharmacy Develops and Launches Best-In-Class Electronic Navigator (eNAV(TM)) Patient Care System
2. Nventa Develops Proprietary Vaccine Adjuvant
3. Bad News to Bad Bugs: Northern Antibiotics Develops Novel Polymyxins With Reduced Toxicity
4. Siemens Corporate Research Develops RAPID2 System for Fast Discovery of Discriminative Pathogen Signatures
5. Binghamton Research Group Develops New Cancer Treatment
6. Saft Develops Super-Phosphate(TM) Technology for Rigorous Defense Applications
7. Panel of Osteoarthritis Experts Develops Optimal Profile of Exogenous Hyaluronic Acid
8. HDT Develops Robotic Arm Technology for DARPAs Revolutionizing Prosthetics 2009 Program
9. Solos Endoscopy, Inc. Develops Relay Lense Adapter System For MammoView® Product Line
10. PharmAthene Develops Thermostable Lyophilized rPA Anthrax Vaccine Under a Challenge Grant From the National Institutes of Health
11. Varian Medical Systems Develops New X-Ray Tube for Use in Security Scanning Systems
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... Research and Markets has announced the ... to 2022" report to their offering. ... patients with kidney failure, it replaces the function of kidneys ... blood and thus the treatment helps to keep the patient ... Increasing number of ESRD patients & substantial ...
(Date:6/23/2016)... Roche (SIX: RO, ROG; OTCQX: RHHBY) announced ... BRAHMS PCT (procalcitonin) assay as a dedicated testing solution ... this clearance, Roche is the first IVD company in ... sepsis risk assessment and management. PCT is ... levels in blood can aid clinicians in assessing the ...
(Date:6/23/2016)... Bracket , a leading clinical trial technology and specialty ... Bracket eCOA (SM) 6.0, at the 52 nd ... in Philadelphia , Pennsylvania.  A demonstration of ... its kind to fully integrate with RTSM, will be held ... a flexible platform for electronic clinical outcomes assessments that is ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... ... Austin residents seeking Mohs surgery services, can now turn to Dr. Jessica ... Peckham for medical and surgical dermatology. , Dr. Dorsey brings specialization to include Mohs ... Mohs Micrographic Surgery completed by Dr. Dorsey was under the direction of Glenn Goldstein, ...
(Date:6/25/2016)... ... ... First Choice Emergency Room , the largest network of independent freestanding emergency ... its new Mesquite-Samuell Farm facility. , “We are pleased to announce Dr. Ogunleye ... M. Muzzarelli, Executive Medical Director of First Choice Emergency Room. , Dr. Ogunleye ...
(Date:6/25/2016)... ... 25, 2016 , ... On Friday, June 10, Van Mitchell, Secretary of the ... to iHire in recognition of their exemplary accomplishments in worksite health promotion. , The ... Health & Wellness Symposium at the BWI Marriott in Linthicum Heights. iHire was one ...
(Date:6/24/2016)... , ... June 24, 2016 , ... Those who have ... these feelings, many turn to unhealthy avenues, such as drug or alcohol abuse, as ... Michigan, has released tools for healthy coping following a traumatic event. , Trauma sufferers ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... Conference and Scientific Sessions in Dallas that it will receive two significant new ... the grants came as PHA marked its 25th anniversary by recognizing patients, medical ...
Breaking Medicine News(10 mins):